- Report
- October 2024
- 195 Pages
Global
From €3305EUR$3,545USD£2,783GBP
€3672EUR$3,939USD£3,092GBP
- Report
- February 2025
- 200 Pages
Global
From €4186EUR$4,490USD£3,525GBP
- Report
- May 2025
- 94 Pages
Global
From €5453EUR$5,850USD£4,592GBP
- Report
- February 2025
- 150 Pages
Global
From €4521EUR$4,850USD£3,807GBP
- Report
- April 2025
- 200 Pages
Global
From €7411EUR$7,950USD£6,241GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1165EUR$1,250USD£981GBP
- Report
- February 2025
- 180 Pages
Global
From €4195EUR$4,500USD£3,533GBP
- Report
- April 2025
- 130 Pages
Global
From €4069EUR$4,365USD£3,427GBP
€4521EUR$4,850USD£3,807GBP
- Report
- May 2024
- 139 Pages
Global
From €6058EUR$6,499USD£5,102GBP
- Report
- May 2024
- 140 Pages
Global
From €6058EUR$6,499USD£5,102GBP
- Report
- November 2020
- 225 Pages
Global
From €13978EUR$14,995USD£11,772GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$4,022USD£3,051GBP
Pasireotide is a drug used to treat thyroid cancer. It is a somatostatin analogue, meaning it works by blocking the release of hormones that stimulate the growth of thyroid cancer cells. Pasireotide is used in combination with other drugs to treat advanced thyroid cancer, and is also used to treat certain types of neuroendocrine tumors. It is available in both injectable and oral forms.
Pasireotide is a relatively new drug, and is still in the early stages of development. It is not yet widely available, and is only approved for use in certain countries. Clinical trials are ongoing to evaluate the safety and efficacy of the drug in different types of thyroid cancer.
Some companies involved in the Pasireotide market include Novartis, Ipsen, and Endo Pharmaceuticals. Show Less Read more
